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Abstract Placental leucine aminopeptidase (P-LAP) is located
preferentially in syncytiotrophoblasts in human placenta. Here
we investigated P-LAP expression and the regulatory mecha-
nisms in BeWo choriocarcinoma cells with forskolin (FSK)-in-
duced di¡erentiation. Morphologically di¡erentiated cells re-
vealed enhanced P-LAP staining. FSK signi¢cantly increased
P-LAP activity and mRNA. Deletion or mutation of activator
protein-2 (AP-2) binding site in the footprint-3 (3216 to 3172)
of P-LAP promoter abrogated the stimulatory e¡ects of FSK
on luciferase activity of the construct 3216/+49. In AP-2-de¢-
cient Hep-G2 cells, FSK failed to stimulate luciferase activity of
the construct 3216/+49. Among the isoforms, BeWo expressed
AP-2K and AP-2Q, while FSK increased only AP-2K. These
results suggest di¡erentiation-dependent P-LAP expression in
trophoblasts, which involves increased AP-2K binding.
8 2003 Federation of European Biochemical Societies. Pub-
lished by Elsevier B.V. All rights reserved.
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1. Introduction
During placental development, cytotrophoblasts di¡erenti-
ate and fuse to syncytiotrophoblasts. Biochemical di¡erentia-
tion including the synthesis of trophoblast-speci¢c hormones
occurs in parallel with this morphological di¡erentiation. Sev-
eral lines of evidence suggest that cAMP plays a signi¢cant
role in stimulating both morphological and biochemical di¡er-
entiation [1,2]. Evidence that intracellular cAMP levels rise
prior to the fusion of cytotrophoblasts [3] and that cAMP
or its analogues stimulate human chorionic gonadotrophin
(hCG) production, a good marker of trophoblast di¡erentia-
tion [4,5], supports this notion.
Placental leucine aminopeptidase (P-LAP) is a predominant
oxytocinase in the placenta and maternal serum [6,7], which is
involved in the maintenance of pregnancy via regulating oxy-
tocin levels. Immunohistochemistry shows predominant local-
ization of P-LAP to syncytiotrophoblasts, but little or no
positive staining in cytotrophoblasts [8,9], suggesting that
P-LAP expression depends on trophoblast di¡erentiation.
However, no in vitro studies have been performed to con¢rm
this observation. We isolated genomic clones containing the
5P-upstream region of the P-LAP gene [10] and found that
transcription factor activator protein-2 (AP-2) and Ikaros co-
operatively enhance P-LAP transcription in trophoblastic cells
[11,12]. In addition to the association with development and
di¡erentiation of adipocytes and keratinocytes [13,14], AP-2
also plays a critical role in spontaneous and cAMP-stimulated
trophoblast di¡erentiation, resulting in the increase of hCG
and human placental lactogen (hPL) expression [15^17]. The
AP-2 family consists of at least three di¡erent genes referred
to as AP-2K, AP-2L, and AP-2Q [18^20], among which AP-2K
and AP-2Q are expressed in human placenta [21]. Our previous
study also suggested an association of AP-2K and AP-2Q with
the basal expression of P-LAP [12]. AP-2K mRNA has been
shown to increase during the di¡erentiation of human tro-
phoblasts [21,22], but to date, changes in AP-2 isoforms at
the protein level have not been con¢rmed.
These ¢ndings led us to hypothesize that P-LAP expression
is regulated in a di¡erentiation-dependent manner involving
AP-2 binding in trophoblastic cells. To test this hypothesis, we
investigated the changes in P-LAP expression and its accom-
panying regulatory mechanisms using BeWo choriocarcinoma
cells exposed to adenylate cyclase activator forskolin (FSK) as
a model for trophoblast di¡erentiation [1].
2. Materials and methods
2.1. Cell culture
BeWo (ATCC CCL-98) and Hep-G2 (ATCC HB 8065) cells were
grown in RPMI 1640 (Sigma) and Dulbecco’s modi¢ed Eagle’s me-
dium (Sigma), respectively, supplemented with 10% heat-inactivated
fetal calf serum, penicillin (100 U/ml), and streptomycin (100 Wg/ml)
at 37‡C in an atmosphere with 5% CO2.
2.2. FSK treatment and P-LAP enzymatic activity
BeWo cells were treated with water-soluble FSK (FSK-NKH477, a
gift from Nippon Kayaku Co, Ltd.) at 50 WM as described [23]. The
amount of hCG secreted in the supernatant of BeWo cell cultures was
determined using an hCG-CTP-ELISA kit (Wako). P-LAP activity
was measured as previously described [6].
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2.3. Immunocytochemistry
BeWo cells were cultured in four-well chamber glass slides (Lab-
Tek) with or without FSK. Immunocytochemical staining was per-
formed as previously described [23] using rabbit anti-P-LAP polyclon-
al antibody (1:500 dilution) [24] and anti-AP-2K, AP-2L and AP-2Q
polyclonal antibodies (Santa Cruz; 1:200 dilution). For negative con-
trols, the primary antibody was replaced by a non-speci¢c IgG at the
same dilution.
2.4. RNA preparation and semi-quantitative reverse transcription-
polymerase chain reaction (RT-PCR)/Southern blot procedure
Total RNA (1 Wg) isolated from cells using an RNeasy kit (Qiagen)
was reverse-transcribed using 2.5 WM random hexamers (Applied Bio-
systems) in 20 Wl reactions. P-LAP was ampli¢ed by PCR in 50 Wl
mixtures under the conditions consisting of 94‡C for 30 s, 62‡C for
30 s and 72‡C for 30 s using 1 Wl aliquots of RT reaction products and
the following primers: P-LAP sense (5P-GGGCACAGATCAGG-
CTTCCCACT-3P) and P-LAP anti-sense (5P-GATCTCAGCTTG-
TTTTTCTTGGCTTG-3P). L-actin was ampli¢ed by RT-PCR using
sense (5P-AACCGCGAGAAGATGACCCAG-3P) and anti-sense (5P-
CTCCTGCTTGCTGATCCACAT-3P) primers under the same PCR
conditions as used for P-LAP. The PCR products (10 Wl) per lane
were resolved by electrophoresis on 1.0% agarose gels, then trans-
ferred to Hybond-Nþ nylon membranes (Amersham Pharmacia Bio-
tech). Southern hybridization proceeded using [32P]P-LAP cDNA and
[32P]L-actin cDNA as probes. P-LAP mRNA levels were normalized
by L-actin expression measured with a BAS 2000 Bioimage Analyzer
(Fuji Photo Film) after autoradiography.
2.5. Construction of luciferase reporter plasmids
The following P-LAP promoter-luciferase constructs were con-
structed by subcloning PCR-derived fragments into the pGL3-Basic
vector (Promega) at the KpnI site as previously described [11,12]:
3216/+49 (includes Ikaros and AP-2 binding sites), 3216M1 (func-
tional for Ikaros and mutant for AP-2 binding), 3216M3 (mutant for
both Ikaros and AP-2 binding), and 3172/+49 (a construct that ex-
cludes both sites).
2.6. Transfections and luciferase assay
Transient transfections were performed using the LipofectAMINE
PLUS1 Reagent (Life Technologies) in six-well plates. Fire£y lucif-
erase reporter plasmid DNA (1 Wg) and 0.1 Wg of pRL-TK plasmid
DNA (internal control to normalize transfection e⁄ciency) were tran-
siently co-transfected into cultured cells. Twenty-four hours after
transfection, cells were incubated with or without 50 WM of FSK
for an additional 12 h and passively lysed with 500 Wl of lysis bu¡er
(Promega). Fire£y and renilla luciferase activities were measured using
a dual-luciferase reporter assay system (Promega). The fold increase
by FSK in ¢re£y luciferase activity, normalized by renilla luciferase
activity, was calculated.
2.7. Statistical analysis
All experiments were performed at least three times, and assays
Fig. 1. Immunocytochemistry of P-LAP in (A) control and (B)
FSK-treated BeWo cells. Control cells were cultured in serum-free
media for 48 h and FSK-treated cells were exposed to FSK (50
WM) for 48 h. Scale bar is 15 Wm.
Fig. 2. Induction of P-LAP activity in BeWo cells by FSK. Results
are shown as a percentage of activity present before FSK treatment.
Data are expressed as meansUS.D. of triplicate samples from at
least three independent experiments. * indicates comparison with
control is signi¢cant at P6 0.05 by the Mann^Whitney U-test.
Fig. 3. Induction of P-LAP mRNA in BeWo cells by FSK. Cells
were treated for 24 h in serum-free medium with 50 WM FSK. Total
cellular RNA was extracted and subjected to semi-quantitative
RT-PCR. A: Graphical representation of signal intensity after auto-
radiography of PCR products over the indicated number of cycles
of RT-PCR. B: Autoradiographs of the semi-quantitative RT-PCR
analysis for P-LAP and L-actin mRNA. C: Signal intensity ratio of
P-LAP to L-actin mRNA. Values represent meansUS.D. of three
independent experiments. * indicates comparison with control is sig-
ni¢cant at P6 0.05 by the Mann^Whitney U-test with Boneferroni
correction.
FEBS 27585 11-9-03 Cyaan Magenta Geel Zwart
K. Iwanaga et al./FEBS Letters 552 (2003) 120^124 121
were performed in triplicate. Data are expressed as meansUS.D. Since
the data were not normally distributed, we employed non-parametric
statistics. Comparisons between groups were made with a Mann^
Whitney U-test for two independent samples and Boneferroni correc-
tion for multiple comparisons. Di¡erences were considered signi¢cant
when the P value was 6 0.05.
3. Results
3.1. Induction of P-LAP expression in FSK-treated BeWo cells
The hCG concentration of the BeWo cell culture superna-
tant was signi¢cantly higher in FSK-treated cells than in non-
treated cells (24 h, nine-fold, P6 0.01; 48 h, 13-fold, P6 0.01;
data not shown), suggesting that the biochemical di¡erentia-
tion of BeWo cells was induced by FSK treatment. Immuno-
cytochemical analysis showed that 48-h FSK-treated cells had
enlarged and lobed nuclei and also had higher P-LAP immu-
noreactivity on the cell surface compared to non-treated cells,
which had uniform and small nuclei (Fig. 1). FSK exposure
provided a small, non-signi¢cant elevation in P-LAP activity
during the ¢rst 12 h of culture, but signi¢cantly increased
P-LAP activity after 24 h and 48 h compared to control cells
(Fig. 2).
3.2. E¡ects of FSK on P-LAP mRNA
BeWo cells were incubated with FSK to examine whether
P-LAP activity induction leads to an increase of P-LAP
mRNA. We determined that 29^31 and 19^21 semi-quantita-
tive RT-PCR cycles gave linear, non-saturating increases of
P-LAP and L-actin products, respectively (Fig. 3A). Represen-
tative Southern blots show that FSK apparently stimulated
P-LAP mRNA expression (Fig. 3B). The band density of
P-LAP was 2.6-fold greater in the presence of FSK
(P6 0.01) when normalized to the corresponding signals for
L-actin by scanning densitometry (Fig. 3C).
3.3. Enhancement of luciferase activity by FSK
We examined the e¡ects of FSK on luciferase activity by
focusing on the AP-2 site in the FP3 (3216 to 3172) region of
the P-LAP gene, because the 5P region up to 31.1 kb of the
P-LAP gene contains no cAMP response elements (CREs;
5P-TGACGTCA-3P) [10]. As shown in Fig. 4A, FSK stimu-
lated luciferase activity approximately two-fold, when con-
struct 3216/+49, which includes both Ikaros and AP-2 bind-
ing sites, was transiently transfected. By contrast, FSK did
not stimulate luciferase activity over the levels obtained
from the pGL3-Basic, when construct 3172/+49 was used.
The mutation eliminating AP-2 binding (construct 3216M1)
reduced the e¡ects of FSK to levels equivalent to the con-
struct 3172/+49. Double mutations eliminating both AP-2
and Ikaros binding sites (construct 3216M3) gave FSK-stim-
ulation levels similar to construct 3216M1 and the construct
3172/+49. To con¢rm the role of AP-2 in FSK-induced
P-LAP promoter activity, we also examined luciferase activity
in Hep-G2 cells, which are known to lack AP-2 (Fig. 4B). In
contrast to BeWo cells, the 3216/+49 constructs failed to
show increases in luciferase activity following FSK stimula-
tion in Hep-G2 cells.
3.4. Induction of AP-2K protein by FSK in BeWo cells
To identify the key AP-2 family members for di¡erentia-
tion-dependent P-LAP gene regulation, we examined the ef-
fects of FSK on AP-2 family protein levels by immunocyto-
chemistry. AP-2K protein increased in nuclei after 24-h FSK
stimulation (Fig. 5C) compared with non-treated cells (Fig.
5A). At 48 h, FSK further induced remarkably high immuno-
reactivity of AP-2K, especially in the morphologically changed
cells with enlarged and lobed nuclei (Fig. 5B). AP-2Q was also
expressed in nuclei and cytoplasm in non-treated cells (Fig.
5F), while FSK failed to enhance the immunoreactivity after
Fig. 4. The e¡ects of FSK on luciferase activity in (A) BeWo and (B) Hep-G2 cells. After transient transfection of luciferase constructs, cells
were incubated with or without 50 WM FSK for 12 h. The fold increase by FSK in ¢re£y luciferase activity, normalized by renilla luciferase ac-
tivity, is presented. An oval and a square indicate the Ikaros and AP-2 binding sites, respectively. Mutations at these sites are indicated by an
x. Data are presented as meansUS.D. of three independent transfection experiments performed in triplicate. * indicates comparison with con-
struct 3172/+49 is signi¢cant at P6 0.05 by the Mann^Whitney U-test with Boneferroni correction.
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48 h (Fig. 5G). We could detect AP-2L expression neither
under basal state (Fig. 5D) nor after FSK treatment (Fig.
5E) in BeWo cells.
4. Discussion
P-LAP is predominantly localized in syncytiotrophoblast
cells in human placenta by immunohistochemistry [8,9] and
in situ hybridization [25]. This prompted us to investigate
di¡erentiation-dependent expression of P-LAP in tropho-
blasts. We report here that P-LAP expression was enhanced
in BeWo cells in which di¡erentiation was induced by FSK
treatment. AP-2 binding to the FP3 region of the P-LAP
promoter was involved in this FSK-stimulated P-LAP expres-
sion. Immunocytochemistry showed that only AP-2K was re-
sponsive to FSK treatment, which is the ¢rst to demonstrate
the changes of AP-2 isoform expression with trophoblast dif-
ferentiation at protein levels.
We used BeWo choriocarcinoma cells in our study. BeWo
cells not only have a high degree of similarity to normal
placental trophoblasts [26], but also can be transformed to
syncytiotrophoblastic cells with morphological and functional
di¡erentiation by cAMP stimulation [1]. In addition, tran-
scription factors that regulate P-LAP gene expression under
basal conditions have been identi¢ed in BeWo [11,12].
The induction of BeWo di¡erentiation, which was con-
¢rmed functionally by measuring hCG levels and morpholog-
ically by light microscopy, was associated with an increase of
both P-LAP immunostaining and activity. These ¢ndings are
consistent with previous observations of predominant P-LAP
localization in syncytiotrophoblasts in human placenta. We
have demonstrated that ultrastructurally P-LAP is expressed
Fig. 5. Immunocytochemistry of AP-2 family members in BeWo cells. Cells were immunostained using AP-2K (A^C), AP-2L (D,E) and AP-2Q
(F,G) antibody under basal state (A,D,F), 24-h FSK treatment (C) and 48-h FSK treatment (B,E,G). Control cells were cultured in serum-free
media and FSK-treated cells were exposed to FSK (50 WM). Scale bar is 15 Wm.
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on the microvilli of syncytiotrophoblasts [27]. BeWo cells, as
well as normal trophoblasts, form a microvillous brush border
during morphological di¡erentiation. Therefore, increased
P-LAP expression in FSK-treated BeWo may be related to
the formation of the brush border.
Generally, cAMP regulates protein expression both at tran-
scriptional and post-translational level [28]. Therefore, we ex-
amined whether FSK increased P-LAP activity via accumula-
tion of mRNA. RT-PCR and Southern blot showed that FSK
increased P-LAP mRNA, a result consistent with observed
increased P-LAP activity. This suggests that the increase in
P-LAP proteins during trophoblast di¡erentiation would be
regulated at the transcriptional level.
The 1.1-kb upstream region of P-LAP lacks consensus
CREs as observed on the hCG-L subunit gene. cAMP in-
creases hCG-L promoter activity via AP-2 binding sites [15].
We previously demonstrated that AP-2 binding to the FP3
region was important for high P-LAP promoter activity in
BeWo under basal conditions [11,12]. We, therefore, postu-
lated that AP-2 binding to FP3 would be, at least in part,
involved in P-LAP transcript induction by FSK. We tested
this hypothesis in two ways. First, we examined the e¡ects
of eliminating AP-2 binding to FP3 region on the promoter
activity in FSK-treated BeWo cells. Mutation of AP-2 binding
site (3216M1 construct) reduced the stimulatory e¡ects of
FSK to levels equivalent to the construct 3172/+49. Secondly,
we used AP-2-de¢cient Hep-G2 cells, since cAMP is unable to
exert its e¡ects via AP-2 in these cells. FSK failed to stimulate
the luciferase activity of the construct 3216/+49 over the con-
struct 3172/+49, which contrasted with the results in BeWo.
These ¢ndings strongly suggest that AP-2 binding to FP3
mediates the e¡ects of FSK on P-LAP mRNA accumulation.
Ikaros did not confer induction in response to cAMP, since
the double mutations of AP-2 and Ikaros gave similar cAMP-
induced luciferase activity as the solo mutation of AP-2.
AP-2 is involved in regulating important genes in tropho-
blasts such as hCG-L [15] and hPL [17]. Interestingly, among
the AP-2 family members, only AP-2K mRNA increases dur-
ing trophoblast di¡erentiation, which resulted in the enhance-
ment of hCG-L expression [21]. This up-regulation of AP-2K
is consistent with the evidence that AP-2K mRNA is predom-
inantly expressed in human term placenta [29]. Immunocyto-
chemistry in this study demonstrated that the nuclear AP-2K
expression was up-regulated in the FSK-treated cells, partic-
ularly in morphologically changed cells, whereas AP-2Q ex-
pression remained stable after FSK treatment. To our knowl-
edge, this is the ¢rst report to show increases in AP-2K
isoform expression at protein levels during trophoblast di¡er-
entiation.
In conclusion, we demonstrated that FSK treatment up-
regulated P-LAP gene expression via AP-2, putatively AP-
2K, in BeWo. Our results suggest that P-LAP is transcription-
ally regulated in a di¡erentiation-dependent fashion during
placental development, and also support the previous ¢nding
that only AP-2K is up-regulated with trophoblast di¡erentia-
tion.
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